StonvexLoading…
StonvexStonvexStonvexCore line items from HCAT's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $70.76M | $311.14M | $236.46M | $160.13M |
Operating Income | $-106.48M | $-160.85M | $-74.77M | $-57.27M |
Net Income | $-111.03M | $-177.97M | $-86.95M | $-64.72M |
EPS (Diluted) | $-1.53 | $-2.55 | $-1.25 | $-0.94 |
Total Assets | $412.20M | $502.64M | $587.13M | $616.18M |
Total Liabilities | $274.06M | $256.86M | $255.21M | $268.63M |
Cash & Equivalents | $59.86M | $50.81M | $40.30M | $50.71M |
Free Cash Flow OCF − CapEx | $18.17M | $-237.00K | $-9.88M | $-9.16M |
Shares Outstanding | 73.75M | 72.03M | 70.62M | 70.27M |